Moderna files to expand conditional marketing authorization for its covid-19 vaccine to include children six months to under six years in the european union

The filing follows the european medicines agency's committee for medicinal products for human use recent decision to adopt a positive opinion recommending marketing authorization for moderna's covid-19 vaccine to include children six years of age and older. cambridge, ma / accesswire / april 29, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has submitted for a variation to the conditional marketing authorization (cma) with the european medicines agency (ema) for the evaluation of a 25 Μg two-dose series of spikevax, the company's vaccine against covid-19, in children six months to under six years of age.
MRNA Ratings Summary
MRNA Quant Ranking